Trial ALS drug shows potential to drag out patient endurance – Microbioz India

An experimental medicine that was recently shown to slow the progression of the neurodegenerative disease amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, has now demonstrated the capacity to also prolong patient survival. The findings come from a clinical trial conducted by investigators at the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) and Amylyx Pharmaceuticals, Inc., the company that produces the medication. Amylyx developed AMX0035, the inve…

Click here to view the original article.